
This is a brief review of some of the more important aspects of pharmacology and clinical management of anticoagulant therapy for venous thromboembolism. Some controversial aspects of treatment with respect to drug dosage, laboratory monitoring, and intensity and duration of therapy have been discussed. Thromboembolic complications can be reduced by extending the duration of anticoagulant therapy to a minimum period of 4 months after hospital discharge. Longer periods of treatment may be necessary in patients with recurrent deep venous thrombosis or pulmonary embolism. Hemorrhagic complications can be minimized by proper attention to laboratory monitoring and awareness of drug interactions and side effects.
Risk, Clinical Trials as Topic, Time Factors, Heparin, Anticoagulants, Thrombophlebitis, Random Allocation, Postoperative Complications, Ambulatory Care, Humans, Drug Therapy, Combination, Blood Coagulation Tests, Warfarin
Risk, Clinical Trials as Topic, Time Factors, Heparin, Anticoagulants, Thrombophlebitis, Random Allocation, Postoperative Complications, Ambulatory Care, Humans, Drug Therapy, Combination, Blood Coagulation Tests, Warfarin
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 16 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
